SEC Filing Summary
Filing identity: The request identifies Fortress Biotech, Inc., but the supplied Form 10-K is for Coronado Biosciences, Inc. It covers the fiscal year ended December 31, 2014, and was signed March 16, 2015. The filing describes a development-stage biopharmaceutical company pursuing a broader strategy of acquiring and developing drug and biomedical-product businesses.
Financial results and position
Amounts below are U.S. dollars; financial statement figures are in millions unless noted. The company reported no revenue from operations or product sales.
| Metric | 2014 | 2013 |
|---|---|---|
| Research and development expense | $10.2 | $25.7 |
| General and administrative expense | $10.4 | $10.1 |
| Operating loss | $20.7 | $35.8 |
| Net loss | $20.4 | $37.2 |
| Basic and diluted loss per share | $0.56 | $1.22 |
| Net cash used in operating activities | $16.3 | $29.6 |
- R&D expense fell 60%, mainly because of reduced TSO development spending after the Crohn’s disease trial results and lower staffing and manufacturing-development costs. G&A rose 3%, including higher stock-based compensation and business-development fees.
- 2014 included a $0.7 million impairment charge related to the abandoned Woburn manufacturing buildout and a $0.3 million loss on an expired product option. A $1.2 million fair-value gain on the CB Pharma investment partly offset expenses; the total reported gain from changes in investment fair value was $0.9 million.
- At year-end, cash and cash equivalents were $49.8 million, marketable securities $20.0 million, and restricted cash $14.6 million. Current assets were $70.5 million versus current liabilities of $4.1 million. Restricted cash included $14.0 million pledged against the IDB loan and $0.6 million securing a lease letter of credit.
- Total assets were $89.3 million, total liabilities $18.8 million, and stockholders’ equity $70.5 million. Debt outstanding was $14.0 million under the IDB note, due February 2016; the note is secured by a pledged money-market account. Its stated year-end interest rate was 2.25%.
- Cash and cash equivalents declined $49.8 million during 2014. Investing activities used $23.3 million, including a $20.0 million purchase of marketable securities and investments; financing activities used $10.2 million, reflecting debt refinancing and restricted-cash transfers, partly offset by $4.1 million of stock proceeds.
- The company reported $41.5 million of future operating lease payments, including a 15-year New York lease; desk-space agreements with Opus Point and TG Therapeutics were expected to reimburse $24.4 million, or 60%, of that lease obligation.
- Fourth-quarter 2014 net loss was $3.7 million, or $0.10 per share, compared with a $9.8 million loss, or $0.27 per share, in fourth-quarter 2013.
Material developments, outlook, and risks
- The TSO program was redirected toward autism spectrum disorder after the U.S. Phase 2 Crohn’s disease TRUST-I study missed its primary endpoint; a European Phase 2 Crohn’s study was also discontinued for lack of efficacy. The company said the ongoing Phase 2 ASD study had sufficient TSO supply to complete, but future supply was uncertain.
- After year-end, Ovamed, the sole TSO supplier and manufacturer, filed for insolvency in Germany. Management was assessing supply alternatives. This creates a material risk to TSO development and may affect related license and supply arrangements.
- CNDO-109, an investigational natural-killer-cell therapy for acute myeloid leukemia, completed dose escalation in its Phase 1/2 trial. The company reported no dose-limiting toxicities in the nine treated patients and planned to assess trial data to determine further development.
- The company reported a cash runway of at least 12 months from December 31, 2014, assuming operations in the normal course. It also raised $10 million through a promissory note in February 2015; the note bears an 8% coupon. No formal revenue or earnings guidance was provided, and management expected continued losses and substantial development and growth-strategy spending.
- The 2014 strategy expanded beyond the two principal drug candidates. CB Pharma raised $42.9 million in net IPO and private-placement proceeds held in trust for a future business combination; Coronado’s investment was approximately 23% and had a reported year-end fair value of $3.9 million. Subsequent initiatives included licenses for a topical Hand-Foot Syndrome product and IV tramadol, and formation of Checkpoint Therapeutics for preclinical antibody programs.
- Other key risks include the early-stage and uncertain clinical programs, dependence on third-party manufacturers and trial contractors, need for additional capital, potential dilution, regulatory and reimbursement uncertainty, competition, and the long-term lease commitments. The filing states that management and the auditor found internal controls effective and the financial-statement audit opinion was unqualified.
Important facts for investors to verify
- Confirm the issuer identity: the supplied filing is Coronado Biosciences, Inc., not Fortress Biotech, Inc.
- Check current liquidity and cash burn against the filing’s 12-month runway statement, including the subsequent $10 million note and its interest and repayment terms.
- Verify the status of Ovamed’s insolvency, TSO supply alternatives, and the company’s rights and payment obligations under the TSO licenses.
- Review subsequent clinical updates for the TSO ASD study and CNDO-109, including whether either program advanced, was paused, or generated new safety or efficacy data.
- Assess the terms, related-party arrangements, reimbursement assumptions, and remaining exposure under the 15-year New York office lease.
- Confirm the status and valuation of CB Pharma and subsequent product licenses, including milestone, royalty, development-cost, and financing commitments.